Main » 2016 » October » 5 » Replicor to Disclose Late Breaking HBV Clinical Data at AASLD 2016
8:33 AM
Replicor to Disclose Late Breaking HBV Clinical Data at AASLD 2016
NEW YORK - Tuesday, October 4th 2016 [ME NewsWire]
(BUSINESS WIRE)-- Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced that the preliminary interim analysis from its latest REP 401 clinical trial has been selected by the American Association for the Study of Liver Disease (AASLD) for presentation during the late-breaking oral abstract session at its annual meeting to be held November 11-15, 2016 in Boston, U.S.A.
The REP 401 protocol (NCT02565719) is a randomized, controlled trial assessing the safety and efficacy of its first in class HBsAg release inhibitor, REP 2139 and a REP 2139 derivative with improved plasma and tissue clearance (REP 2165) in combination with tenofovir disoproxil fumarate (TDF) and pegylated interferon alpha 2a (peg-IFN) in treatment naïve patients with chronic HBeAg negative HBV infection. The selection of Replicor’s clinical data for presentation during the late breaking oral abstract session on November 15th, 2016 highlights the recognition of NAP-based therapy as an important new approach for achieving functional cure in patients with chronic HBV.
Complete 6 month follow-up data from the REP 301 protocol (NCT02233075) assessing the safety and efficacy of REP 2139 in combination with peg-IFN in patients with chronic HBV / HDV co-infection will also be presented during the poster session on November 14th, 2016.
These presentations will expand on the existing clinical data demonstrating the unique ability of NAP-based combination therapy to eliminate serum HBsAg and to achieve functional cure in patients with HBV and HBV / HDV co-infection.
Replicor’s presentations from AASLD 2016 will be available on the company’s website following their disclosure at the meeting at www.replicor.com/science/conference-presentations. For further information about the 2016 AASLD Meeting visit: http://www.aasld.org/events-professional-development/liver-meeting.
About Replicor
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.
Contacts
For Replicor Inc.
Alexandra Peterson, 212-508-9709
apeterson@makovsky.com
Permalink: http://www.me-newswire.net/news/18796/en
I am so happy, i never believe i will be this happy again in life, I was working as an air-hoster ( cabby crew ) for 3years but early 2016, i loose my job because of this deadly disease called Hepatitis B (HbsAg), I never felt sick or have any symptom, till all workers were ask to bring their doctor report, that was how i got tested and i found out that am HbsAg positive that make me loose my job, because it was consider as an STD and is incurable disease, i was so depress was thinking of committing suicide, till i explain to a friend of mine, who always said to me a problem share is a problem solved, that was how she directed me to this MED LAB, that was how i contacted them and i get medication from them and i got cured for real, I just went back to my work and they also carry out the test to be real sure and i was negative. Please contact this MED LAB if you are hepatitis B positive or any kind of diseases their email is: medlab36@gmailcom
